X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Affini-T will leverage ElevateBio BaseCamp’s LentiPeak™ lentiviral vector technology platform and cell therapy production capabilities to advance its investigational oncogenic driver programs into clinical development.
Lead Product(s): TCR-engineered T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ElevateBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 15, 2022
Details:
AFNT-111, a preclinically safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation, candidates that support further clinical translation and development.
Lead Product(s): AFNT-111
Therapeutic Area: Oncology Product Name: AFNT-111
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
The partnership will leverage Metagenomi’s proprietary gene editing systems to complement Affini-T’s state-of-the-art TCR discovery and synthetic biology platforms to generate groundbreaking cell therapy products including AFNT-111.
Lead Product(s): AFNT-111
Therapeutic Area: Oncology Product Name: AFNT-111
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Metagenomi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 15, 2022
Details:
With proceeds from this financing, the company will operationalize its platform discovery engine and seek to drive multiple oncogene driver programs into the clinic while pursuing complementary technology licenses to bolster its cell therapy platform.
Lead Product(s): TCR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vida Ventures
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
